Dermapharm Holding SE (DE:DMP)
XETRA:DMP
DMP Stock Chart & Stats
€43.05
€0.00(0.00%)
At close: 4:00 PM EST
€43.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€31.70 - €47.25
Previous CloseN/A
Volume747.00
Average Volume (3M)18.50K
Market Cap
€2.32B
Enterprise Value€3.17B
Total Cash (Recent Filing)€146.58M
Total Debt (Recent Filing)€1.01B
Price to Earnings (P/E)14.4
Beta0.56
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.34%
Share Statistics
EPS (TTM)0.69
Shares Outstanding53,840,000
10 Day Avg. Volume17,993
30 Day Avg. Volume18,498
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.47
Price to Sales (P/S)1.77
P/FCF Ratio12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.00Price Target Upside-21.02% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.52
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
Branded Product LaunchesAnalyst highlights that organic expansion through new branded launches in dermatology and allergology can boost revenue growth and support market share gains.
Portfolio Optimisation And Margin ImprovementPortfolio optimisation and removal of unprofitable product volumes have supported higher margins, improving overall profitability prospects as the company focuses on more profitable lines.
Share Buyback And CancellationA public tender offer to repurchase a material portion of shares at a premium, with planned cancellation of repurchased shares, signals shareholder‑friendly capital allocation and should increase earnings per share for remaining holders.
Bears Say
Conservative Company GuidanceCompany guidance pointing to only modest revenue growth and slight margin improvement suggests limited operational upside from current plans.
Liquidity And Ownership ConcentrationA sharp reduction in free float and a major shareholder becoming more dominant could reduce trading liquidity and make it harder for minority investors to transact the stock.
Reorganisation And Execution RiskOngoing reorganisation and a cautious outlook for Arkopharma point to execution risk, with structural changes not yet translating into stronger results and other units failing to fully offset shortfalls.
Dermapharm Holding SE News
DMP FAQ
What was Dermapharm Holding SE’s price range in the past 12 months?
Dermapharm Holding SE lowest stock price was €31.70 and its highest was €47.25 in the past 12 months.
What is Dermapharm Holding SE’s market cap?
Dermapharm Holding SE’s market cap is €2.32B.
When is Dermapharm Holding SE’s upcoming earnings report date?
Dermapharm Holding SE’s upcoming earnings report date is May 20, 2026 which is in 40 days.
How were Dermapharm Holding SE’s earnings last quarter?
Dermapharm Holding SE released its earnings results on Mar 10, 2026. The company reported €0.69 earnings per share for the quarter, beating the consensus estimate of €0.41 by €0.28.
Is Dermapharm Holding SE overvalued?
According to Wall Street analysts Dermapharm Holding SE’s price is currently Overvalued.
Does Dermapharm Holding SE pay dividends?
Dermapharm Holding SE pays a Annually dividend of €0.9 which represents an annual dividend yield of 2.34%. See more information on Dermapharm Holding SE dividends here
What is Dermapharm Holding SE’s EPS estimate?
Dermapharm Holding SE’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dermapharm Holding SE have?
Dermapharm Holding SE has 53,840,000 shares outstanding.
What happened to Dermapharm Holding SE’s price movement after its last earnings report?
Dermapharm Holding SE reported an EPS of €0.69 in its last earnings report, beating expectations of €0.41. Following the earnings report the stock price went up 8.519%.
Which hedge fund is a major shareholder of Dermapharm Holding SE?
Currently, no hedge funds are holding shares in DE:DMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dermapharm Holding SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.13%
12-Months-Change
Fundamentals
Return on Equity
18.56%
Trailing 12-Months
Asset Growth
4.98%
Trailing 12-Months
Company Description
Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
DMP Stock 12 Month Forecast
Average Price Target
€34.00
▼(-21.02% Downside)
Technical Analysis
Options Prices
Currently, No data available
---